Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FP 1039

Drug Profile

FP 1039

Alternative Names: Fibroblast growth factor ligand trap; FP-1039; GSK 3052230; HGS 1036

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Five Prime Therapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Type 1 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Mesothelioma; Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease) in United Kingdom (IV, Infusion)
  • 24 Jun 2018 Biomarkers information updated
  • 22 Nov 2017 FP 1039 is still in phase I trials for Non-small cell lung cancer (Combination therapy, Late-stage disease) and Mesothelioma (Combination therapy, Late-stage disease) in United Kingdom, Belgium, Denmark, France, the Netherlands, Spain, Russia and USA (NCT01868022)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top